References
- BursteinHJThe distinctive nature of HER2-positive breast cancersN Engl J Med20053531652165416236735
- KlapperLGlatheSVaismanNThe ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factorsProc Natl Acad Sci U S A1999964995500010220407
- CitriASkariaKBYardenYThe deaf and the dumb: the biology of ErbB-2 and ErbB-3Exp Cell Res2003284546512648465
- RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist20091432036819346299
- TzaharEWatermanHChenXA hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorMol Cell Biol199616527653878816440
- YardenYSliwkowskiMXUntangling the ErbB signalling networkNature Rev Mol Cell Biol2001212713711252954
- LeahyBDJStructure and function of the epidermal growth factor (EGF/ErbB) family of receptorsAdv Protein Chem20046812715500857
- HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med2007357395117611206
- PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol2008261231123818250349
- KruserTJWheelerDLMechanisms of resistance to HER family targeting antibodiesExp Cell Res20103161083110020064507
- MountziosGSanoudouDSyrigosKNClinical pharmacogenetics in oncology: the paradigm of molecular targeted therapiesCurr Pharm Des2010162184219320459386
- TaiWMahatoRChengKThe role of HER2 in cancer therapy and targeted drug deliveryJ Control Release201014626427520385184
- LowerEEGlassEBlauRHarmanSHER-2/neu expression in primary and metastatic breast cancerBreast Cancer Res Treat200911330130618273700
- NahtaRYuDHungMCHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerNat Clin Pract Oncol2006326928016683005
- FriedländerEBarokMSzöllosiJVerebGErbB-directed immunotherapy: antibodies in current practice and promising new agentsImmunol Lett200811612614018201769
- CallahanRHurvitzSHuman epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent diseaseCurr Opin Obstet Gynecol201123374321500375
- WeigeltBGeyerFCReis-FilhoJSHistological types of breast cancer: how special are they?Mol Oncol2010419220820452298
- GewirtzDAA critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochem Pharmacol19995772774110075079
- CampiglioMSomenziGOlgiatiCRole of proliferation in HER2 status predicted response to doxorubicinInt J Cancer200310556857312712452
- DangCFornierMSugarmanSThe safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerJ Clin Oncol2008261216122218323546
- FerencPSolárPMikešJKoval’JFedoročkoPBreast cancer and current therapeutic approaches: from radiation to photodynamic therapyGunduzMGunduzEBreast Cancer: Current and Alternative Therapeutic ModalitiesRijeka, CroatiaInTech20116387
- DeboerCMeulmanPAWnukRJPetersonDHGeldanamycin, a new antibioticJ Antibiot1970234424475459626
- ToftDORecent advances in the study of hsp90 structure and mechanism of actionTrends Endocrinol Metab1998923824318406275
- NeckersLSchulteTWMimnaughEGeldanamycin as a potential anti-cancer agent: its molecular target and biochemical activityInvest New Drugs19991736137310759403
- BishtKSBradburyCMMattsonDGeldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicityCancer Res2003638984899514695217
- MussHBThorADBerryDAc-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerN Engl J Med1994330126012667908410
- PetitTBorelCGhnassiaJNew therapeutic targets in the intrinsic apoptotic pathway in neuroblastomaClin Cancer Res200171577158111410493
- WangSKonorevEAKotamrajuSJosephJKalivendiSKalyanaramanBDoxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanismsJ Biol Chem2004279255352554315054096
- GamenSAnelaAPérez-GalánPDoxorubicin treatment activates a Z-VAD-sensitive caspase, which causes Δψm loss, caspase-9 activity, and apoptosis in Jurkat cellsExp Cell Res200025822323510912804
- Bar-OnOShapiraMHershkoDDDifferential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cellsAnticancer Drugs2007181113112117893511
- PotterAJGollahonKAPalancaBJAFlow cytometric analysis of the cell cycle phase specificity of DNA damage induced by radiation, hydrogen peroxide and doxorubicinCarcinogenesis20022338940111895853
- PegramMHsuSLewisGInhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene1999182241225110327070
- BaselgaJNortonLAlbanellJKimYMendelsohnJRecombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsCancer Res199858282528319661897
- HosteinIRobertsonDDistefanoFWorkmanPClarkePAInhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosisCancer Res2001614003400911358818
- HelmbrechtKZeiseERensingLChaperones in cell cycle regulation and mitogenic signal transduction: a reviewCell Prolif20003334136511101008
- ShimamuraTLowellAMEngelmanJAShapiroGIEpidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsCancer Res2005656401640816024644
- KimSKangJHuWEversBMChungDHGeldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomasInt J Cancer200310335235912471618
- ParkJYehMWWongMGThe heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell linesJ Endocrinol Metab20038833463353
- GeorgakisGVLiYYounesAThe heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9Br J Haematol2006135687116925576
- AligueRAkhavan-NiakHRussellPA role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90EMBO J1994136099601067813446
- StepanovaLLengXParkerSBHarperJ WMammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4Genes Dev199610149115028666233